Mazdutide peptide dosage in human trials starts at 2 mg weekly and escalates to 4 mg or 6 mg. Learn the published protocols, side effects, and safety limits.
Mazdutide has no approved dose for humans, so the only real dosage numbers come from clinical trials. Those trials used once-weekly subcutaneous injections starting at 2 mg and escalating to 4 mg or 6 mg as tolerance allowed. That is a research protocol, not a prescription, and anyone weighing mazdutide should speak with a licensed healthcare professional before considering it.
What Is Mazdutide?
Mazdutide (development code IBI362) is an investigational dual receptor agonist that activates both the GLP-1 and glucagon receptors. It is an oxyntomodulin analog, meaning it mimics a gut hormone that influences appetite and energy expenditure.
Innovent Biologics developed the compound, and most of the human data comes from trials in China in adults with overweight, obesity, or type 2 diabetes. Online it is often shortened to "maz peptide," but it is an investigational drug rather than a supplement.
Mazdutide is not FDA-approved for human use in the United States, which is why no official mazdutide peptide dosage appears on any pharmacy label.
Mazdutide Dosage in Published Trials
Published studies use a low starting dose followed by careful escalation. The table below summarizes protocols that have appeared in peer-reviewed reports and company disclosures.
| Trial / setting | Starting dose | Escalation | Maintenance dose | Schedule |
|---|---|---|---|---|
| Phase 2 dose-finding, obesity | 3 mg | None | 3 mg, 4.5 mg, or 6 mg | Once weekly for 24 weeks |
| Phase 2 dose-finding, type 2 diabetes | 3 mg | None | 3 mg, 4.5 mg, or 6 mg | Once weekly for about 20 weeks |
| Phase 3 GLORY-1, obesity | 2 mg | 2 mg to 4 mg to 6 mg, stepped every 4 weeks | 4 mg or 6 mg | Once weekly for 48 weeks |
| Phase 3 DREAMS-1 and DREAMS-2, type 2 diabetes | 2 mg | 2 mg to 4 mg, then 6 mg if tolerated | 4 mg or 6 mg | Once weekly |
Each row reflects a specific trial design, and none of these numbers should be read as a personal dosing recommendation. Trial participants were monitored by physicians, received regular lab work, and could be removed from a study if side effects became unmanageable.
Reported human data suggest mazdutide's half-life is roughly one week, which is the main reason every protocol uses weekly injections instead of daily ones. A long half-life keeps the drug active between doses, but it also means side effects can linger when a dose is too high.
Understanding the Mazdutide Starting Dose
The phase 3 program began at 2 mg once weekly and held that dose for about four weeks before increasing. The earlier phase 2 studies started at 3 mg and used 3 mg, 4.5 mg, or 6 mg as fixed maintenance doses.
Dose escalation exists to give the digestive system time to adapt. Nausea, vomiting, and diarrhea are the leading reasons people stop GLP-1 class medications early, and a slow ramp-up lowers those odds.
Common escalation principles in these trials include:
- Start low and stay at the starting dose for at least four weeks.
- Increase in small steps rather than jumping to the target dose.
- Hold at the current dose if side effects have not settled.
- Never double a missed weekly dose to catch up.
A mazdutide dosing chart copied from a forum usually blends phase 2 and phase 3 numbers without saying which is which. That is one reason dose charts for investigational drugs are unreliable.
Side Effects and Safety Considerations
The most frequently reported side effects in trials were gastrointestinal: nausea, vomiting, diarrhea, and reduced appetite. Injection site reactions and fatigue were also reported.
As with other GLP-1 receptor agonists, clinicians monitor for pancreatitis, gallbladder problems, and kidney injury caused by dehydration. People with a personal or family history of medullary thyroid carcinoma or MEN2 are generally advised to avoid this drug class.
Mazdutide is not FDA-approved for human use in the United States, and long-term safety data beyond the trial periods do not exist yet. Anyone who is pregnant, breastfeeding, or managing another chronic condition should treat those facts as reasons to get medical clearance first.
Many people ask about stacking mazdutide with tirzepatide, but no trial has tested that combination. Both drugs act on GLP-1 receptors, so pairing them raises the risk of severe nausea, dehydration, and other serious side effects.
Sourcing, Labeling, and Research-Use Products
Vials sold online are labeled for research use only and are not intended for human consumption. Vendors such as Toppeptides present mazdutide alongside other research compounds, and that framing applies to most suppliers in this space.
Reputable suppliers provide a third-party certificate of analysis for each lot, print the batch number on the vial, and ship with cold packs. A verified peptide promo code says nothing about purity, sterility, or whether the material in the vial matches the label.
The same sourcing questions apply to unrelated compounds discussed in the same communities. The bp157 peptide, for example, is also an unapproved research chemical, and labs that buy peptides in bulk typically request documentation for every lot for that reason.
Questions to Ask a Healthcare Professional
If you are considering mazdutide, bring a written list to the appointment rather than a dosage chart from the internet.
- Am I a candidate for an approved GLP-1 or dual agonist medication instead?
- How would this interact with my current prescriptions?
- What symptoms should send me to urgent care?
- How often would my kidney, liver, and pancreatic markers be checked?
- What happens if I need to stop the medication suddenly?
No online dosing chart replaces individualized medical supervision, especially for a drug that is still investigational.
Frequently Asked Questions
What is the starting dose of mazdutide?
In the phase 3 trials, the starting dose was 2 mg injected subcutaneously once weekly, held for about four weeks before increasing to 4 mg and then 6 mg. Earlier phase 2 studies started at 3 mg. These are research protocols, not approved prescribing guidance.
Is mazdutide the same as tirzepatide?
No. Mazdutide targets the GLP-1 and glucagon receptors, while tirzepatide targets GIP and GLP-1. They are different molecules studied in separate trials, they are not interchangeable, and no study has tested them together.
How long does mazdutide stay in your system?
Reported human data suggest a half-life of about one week, so most of a single dose clears within roughly four to five weeks. Weekly dosing keeps steady levels in the body, and appetite effects typically fade over several weeks after stopping.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.